What is the share price of Gujarat Themis Biosyn Ltd (GUJTHEM) today?
The share price of GUJTHEM as on 29th May 2026 is ₹404.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The past returns of Gujarat Themis Biosyn Ltd (GUJTHEM) share are- Past 1 week: 11.90%
- Past 1 month: 8.79%
- Past 3 months: 31.14%
- Past 6 months: -1.17%
- Past 1 year: 29.38%
- Past 3 years: 41580.41%
- Past 5 years: 66.06%
What are the peers or stocks similar to Gujarat Themis Biosyn Ltd (GUJTHEM)?
The peers or stocks similar to Gujarat Themis Biosyn Ltd (GUJTHEM) include:What is the dividend yield % of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The current dividend yield of Gujarat Themis Biosyn Ltd (GUJTHEM) is 0.16.What is the market cap of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹4709.48 Cr as of 29th May 2026.What is the 52 week high and low of Gujarat Themis Biosyn Ltd (GUJTHEM) share?
The 52-week high of Gujarat Themis Biosyn Ltd (GUJTHEM) is ₹479 and the 52-week low is ₹225.05.What is the PE and PB ratio of Gujarat Themis Biosyn Ltd (GUJTHEM) stock?
The P/E (price-to-earnings) ratio of Gujarat Themis Biosyn Ltd (GUJTHEM) is 100.89. The P/B (price-to-book) ratio is 18.96.Which sector does Gujarat Themis Biosyn Ltd (GUJTHEM) belong to?
Gujarat Themis Biosyn Ltd (GUJTHEM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gujarat Themis Biosyn Ltd (GUJTHEM) shares?
You can directly buy Gujarat Themis Biosyn Ltd (GUJTHEM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gujarat Themis Biosyn Ltd
GUJTHEM Share Price
NSE₹404.306.46% (-27.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GUJTHEM Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GUJTHEM Performance & Key Metrics
GUJTHEM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 100.89 | 18.96 | 0.16% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.84 | 6.22 | 0.48% |
GUJTHEM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GUJTHEM Company Profile
Gujarat Themis Biosyn Ltd manufactures pharmaceuticals focusing on active pharmaceutical ingredients (APIs) like Rifamycin-S and Lovastatin, primarily through fermentation processes.
SUNPHARMA
PE Ratio
37.61
37.61
1Y Return
5.85%
5.85%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.82
69.82
1Y Return
39.53%
39.53%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.17
29.17
1Y Return
5.14%
5.14%
Buy Reco %
62.86
62.86
DRREDDY
PE Ratio
25.87
25.87
1Y Return
4.43%
4.43%
Buy Reco %
51.52
51.52
ZYDUSLIFE
PE Ratio
21.52
21.52
1Y Return
16.54%
16.54%
Buy Reco %
53.57
53.57
GUJTHEM Forecast
GUJTHEM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GUJTHEM
GUJTHEM
Income
Balance Sheet
Cash Flow
Quarterly Normal View
GUJTHEM Income Statement
GUJTHEM Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 39.86 | 43.03 | 39.35 | 35.04 | 39.76 | 39.08 | 36.15 | 43.17 | 43.78 | 45.15 | ||||||||||
Operating & Other expenses | 21.11 | 21.08 | 20.28 | 19.33 | 20.65 | 21.70 | 21.95 | 21.41 | 22.06 | 24.87 | ||||||||||
EBITDA | 18.75 | 21.95 | 19.07 | 15.71 | 19.11 | 17.38 | 14.20 | 21.76 | 21.72 | 20.28 | ||||||||||
| Depreciation/Amortization | 0.98 | 0.92 | 1.15 | 1.44 | 1.56 | 1.23 | 2.03 | 2.96 | 3.89 | 4.04 | ||||||||||
| PBIT | 17.77 | 21.03 | 17.92 | 14.27 | 17.55 | 16.15 | 12.17 | 18.80 | 17.83 | 16.24 | ||||||||||
| Interest & Other Items | 0.08 | 0.07 | 0.07 | 0.08 | 0.14 | 0.07 | 0.04 | 0.04 | 0.96 | 1.91 | ||||||||||
| PBT | 17.69 | 20.96 | 17.85 | 14.19 | 17.41 | 16.08 | 12.13 | 18.76 | 16.87 | 14.33 | ||||||||||
| Taxes & Other Items | 4.68 | 5.07 | 4.62 | 3.63 | 4.43 | 4.09 | 3.06 | 4.49 | 4.41 | 3.45 | ||||||||||
| Net Income | 13.01 | 15.89 | 13.23 | 10.56 | 12.98 | 11.99 | 9.07 | 14.27 | 12.46 | 10.88 | ||||||||||
| EPS | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 |
GUJTHEM Company Updates
FY 2026FY 2026
Investor Presentation
May 25PDF
May 22PDF
Apr 23PDF
+3 more
GUJTHEM Stock Peers
GUJTHEM Past Performance & Peer Comparison
GUJTHEM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gujarat Themis Biosyn Ltd | 100.89 | 18.96 | 0.16% |
| Sun Pharmaceutical Industries Ltd | 37.61 | 5.96 | 0.89% |
| Torrent Pharmaceuticals Ltd | 69.82 | 19.67 | — |
| Cipla Ltd | 29.17 | 3.62 | 0.93% |
GUJTHEM Stock Price Comparison
Compare GUJTHEM with any stock or ETFCompare GUJTHEM with any stock or ETF
GUJTHEM
GUJTHEM Holdings
GUJTHEM Shareholdings
GUJTHEM Promoter Holdings Trend
GUJTHEM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GUJTHEM Institutional Holdings Trend
GUJTHEM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GUJTHEM Shareholding Pattern
GUJTHEM Shareholding Pattern
GUJTHEM Shareholding History
GUJTHEM Shareholding History
Foreign Institutions
Mutual Funds Invested in GUJTHEM
Mutual Funds Invested in GUJTHEM
No mutual funds holding trends are available
Top 3 Mutual Funds holding Gujarat Themis Biosyn Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7689% | Percentage of the fund’s portfolio invested in the stock 5.41% | Change in the portfolio weight of the stock over the last 3 months 0.63% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/40 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1992% | Percentage of the fund’s portfolio invested in the stock 0.53% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/47 (-10) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0003% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 86/130 (-4) |
Compare 3-month MF holding change on Screener
smallcases containing GUJTHEM stock
smallcases containing GUJTHEM stock
Looks like this stock is not in any smallcase yet.
GUJTHEM Events
GUJTHEM Events
GUJTHEM Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.55 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GUJTHEM Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.55 every year
GUJTHEM Upcoming Dividends
GUJTHEM Upcoming Dividends
No upcoming dividends are available
GUJTHEM Past Dividends
GUJTHEM Past Dividends
Cash Dividend
Ex DateEx DateSep 4, 2025
Final
Final | Div/Share: ₹0.67
Dividend/Share
₹0.67
Ex DateEx Date
Sep 4, 2025
Cash Dividend
Ex DateEx DateJul 15, 2024
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateFeb 22, 2024
Interim
Interim | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Feb 22, 2024
Cash Dividend
Ex DateEx DateSep 1, 2023
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 1, 2023
Cash Dividend
Ex DateEx DateDec 1, 2022
Interim
Interim | Div/Share: ₹4.40
Dividend/Share
₹4.40
Ex DateEx Date
Dec 1, 2022
GUJTHEM Stock News & Opinions
GUJTHEM Stock News & Opinions
Articles & Videos
Corporate
Corporate
Board of Gujarat Themis Biosyn recommends final dividendGujarat Themis Biosyn announced that the Board of Directors of the Company at its meeting held on 25 May 2026, inter alia, have recommended the final dividend of Rs 0.67 per equity Share (i.e. 67%) , subject to the approval of the shareholders.
5 days agoCapital Market - Live
Earnings
Earnings
Gujarat Themis Biosyn standalone net profit declines 9.25% in the March 2026 quarterNet profit of Gujarat Themis Biosyn declined 9.25% to Rs 10.89 crore in the quarter ended March 2026 as against Rs 12.00 crore during the previous quarter ended March 2025. Sales rose 17.20% to Rs 44.23 crore in the quarter ended March 2026 as against Rs 37.74 crore during the previous quarter ended March 2025. For the full year,net profit declined 4.29% to Rs 46.68 crore in the year ended March 2026 as against Rs 48.77 crore during the previous year ended March 2025. Sales rose 9.96% to Rs 165.82 crore in the year ended March 2026 as against Rs 150.80 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales44.2337.74 17 165.82150.80 10 OPM %43.7942.50 -45.5545.65 - PBDT18.3817.32 6 75.0170.91 6 PBT14.3416.09 -11 62.0965.54 -5 NP10.8912.00 -9 46.6848.77 -4 Powered by Capital Market - Live
5 days agoCapital Market - Live
Spotlight
Spotlight
Gujarat Themis Biosyn jumps on acquisition of Japan-based MicroBiopharmThe company has signed a definitive agreement to acquire 100% equity stake in MBJ through a wholly owned special purpose vehicle to be incorporated in Japan. The transaction is expected to close in Q2 FY27, subject to regulatory approvals and customary closing conditions. MBJ is engaged in fermentation-based research, development and manufacturing of pharmaceuticals, specialty chemicals and CDMO services. The Japanese company has capabilities across oncology APIs, plasmid DNA manufacturing, ADC conjugation and biologics. MBJ reported estimated revenue of JPY 9.5 billion, or around Rs 570 crore, for FY26. Around 40% of its revenue comes from overseas markets outside Japan. Gujarat Themis said the acquisition marks a strategic step in its transition from a fermentation-led intermediates business to a technology-driven Contract Development and Manufacturing Organisation (CDMO) platform focused on precision fermentation and next-generation drug manufacturing. The company added that the deal will provide access to MBJ's proprietary technologies, global customer relationships and regulated manufacturing infrastructure. Two of MBJ's three manufacturing facilities in Japan have undergone audits by the US FDA and Japan's PMDA. The acquisition is proposed to be funded through a mix of debt and equity and is expected to be earnings accretive. Gujarat Themis Biosyn is a pharmaceutical company engaged in the development, manufacturing and marketing of fermentation-based pharmaceutical intermediates and APIs across key therapeutic segments in India. The company specializes in fermentation-based product development and continues to expand its presence across the Indian and global markets with a focus on building an integrated and scalable pharmaceutical platform. On a standalone basis, Gujarat Themis Biosyn's net profit declined 3.93% to Rs 12.46 crore while net sales rose 9.74% to Rs 43.37 crore in Q3 December 2025 over Q3 December 2024. Powered by Capital Market - Live
5 days agoCapital Market - Live
Corporate
Corporate
Gujarat Themis Biosyn to conduct board meetingGujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 May 2026.
1 week agoCapital Market - Live
Earnings
Earnings
Gujarat Themis Biosyn standalone net profit declines 3.93% in the December 2025 quarterNet profit of Gujarat Themis Biosyn declined 3.93% to Rs 12.46 crore in the quarter ended December 2025 as against Rs 12.97 crore during the previous quarter ended December 2024. Sales rose 9.74% to Rs 43.37 crore in the quarter ended December 2025 as against Rs 39.52 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales43.3739.52 10 OPM %49.1147.72 - PBDT20.7618.96 9 PBT16.8717.40 -3 NP12.4612.97 -4 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Gujarat Themis Biosyn to conduct board meetingGujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Earnings
Gujarat Themis Biosyn standalone net profit rises 34.91% in the September 2025 quarterNet profit of Gujarat Themis Biosyn rose 34.91% to Rs 14.26 crore in the quarter ended September 2025 as against Rs 10.57 crore during the previous quarter ended September 2024. Sales rose 21.98% to Rs 42.35 crore in the quarter ended September 2025 as against Rs 34.72 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales42.3534.72 22 OPM %49.4244.35 - PBDT21.7115.64 39 PBT18.7514.20 32 NP14.2610.57 35 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Gujarat Themis Biosyn to convene board meetingGujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Gujarat Themis Biosyn AGM scheduledGujarat Themis Biosyn announced that the Annual General Meeting(AGM) of the company will be held on 12 September 2025.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Earnings
Gujarat Themis Biosyn standalone net profit declines 31.57% in the June 2025 quarterNet profit of Gujarat Themis Biosyn declined 31.57% to Rs 9.06 crore in the quarter ended June 2025 as against Rs 13.24 crore during the previous quarter ended June 2024. Sales declined 7.62% to Rs 35.87 crore in the quarter ended June 2025 as against Rs 38.83 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales35.8738.83 -8 OPM %38.8147.80 - PBDT14.1519.01 -26 PBT12.1217.86 -32 NP9.0613.24 -32 Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.92%, vs industry avg of 9.86%
Over the last 5 years, market share increased from 0.03% to 0.04%
Over the last 5 years, net income has grown at a yearly rate of 15.56%, vs industry avg of 19.71%